Chimerix

News Releases

2010

CMX157 shows potential to treat multi-drug-resistant HIV and improve the activity and toxicity profile of Tenofovir

   

RESEARCH TRIANGLE PARK, NC, July 28, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively… > Read More

Chimerix appoints two new Vice Presidents to Clinical Management Team

   

RESEARCH TRIANGLE PARK, NC, July 21, 2010 Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that it has expanded its clinical management team with the appointment of Timothy King, MSPH, as Vice President of Clinical Operations… > Read More

Chimerix initiates Phase 1 Study of CMX157

   

-New HIV Compound to Be Evaluated for Safety, Tolerability and Active Antiviral Drug Levels

RESEARCH TRIANGLE PARK, NC, May 13, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement… > Read More

Chimerix appoints Thomas Pitler, Ph.D., VP, Business Development

   

RESEARCH TRIANGLE PARK, NC, May 6, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Thomas A. Pitler, Ph.D., has joined the company as Vice President, Business Development.

Dr. Pitler brings to… > Read More

Chimerix names George Painter, PhD, Chairman of the Board & CSO; appoints Kenneth Moch, President & CEO

   

RESEARCH TRIANGLE PARK, NC, May 4, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer.  Mr. Moch joined Chimerix as Chief Operating… > Read More

Chimerix to Present at Future Leaders in the Biotech Industry Conference

   

Research Triangle Park, NC, March 29, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at the upcoming Future Leaders in the… > Read More

Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus

   

- New Broad-Spectrum Antiviral Agent to Be Evaluated for Preventative and Therapeutic Activity

RESEARCH TRIANGLE PARK, NC, March 9, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation… > Read More

Chimerix CEO George Painter, Ph.D., to Speak at Institute of Medicine Workshop

   

- Special Panel to Focus on Enhancing Innovation Necessary for the Approval of New National Emergency Medicine Countermeasure Products

RESEARCH TRIANGLE PARK, NC, February 23, 2010 - Chimerix, Inc., a biotechnology company developing orally-available… > Read More

Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer

   

RESEARCH TRIANGLE PARK, NC, February 04, 2010 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer.

Dr.… > Read More

2009

Chimerix to Present at Two Upcoming Investor Conferences

   

RESEARCH TRIANGLE PARK, NC, November 12, 2009 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a… > Read More

 1 2 3 >